Dapa Met Xr 10/500 Mg Tablet – Extended-Release Dual Therapy for Type 2 Diabetes
Dapa Met Xr 10/500 Mg Tablet – Extended-Release Dual Therapy for Type 2 Diabetes
Dapa Met Xr 10/500 Mg Tablet – Extended-Release Dual Therapy for Type 2 Diabetes
Description
Dapa Met Xr 10/500 Mg Tablet – All-Day Blood Sugar Control with Added Heart & Kidney Protection
Dapa Met Xr 10/500 Mg Tablet combines dapagliflozin 10 mg (SGLT2 inhibitor) and metformin 500 mg in an extended-release formulation to deliver smooth, 24-hour glycemic control for adults with type 2 diabetes. Dapagliflozin removes excess glucose through urine while metformin reduces liver glucose production and improves insulin sensitivity. The XR technology ensures steady release, minimizing GI side effects and providing consistent coverage with just one daily dose. Clinically proven to lower HbA1c, support modest weight loss, and reduce the risk of heart failure and kidney disease progression, it is an excellent choice for patients needing enhanced therapy beyond monotherapy.
